文献速递基础与转化研究新药、器械与细胞基因治疗研发

CD229 CAR T细胞的系统性单氨基酸亲和力调谐保留抗多发性骨髓瘤疗效并消除靶向非肿瘤毒性

Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity.
PubMed 文献 · Sci Transl Med · 2023-07-19

研究通过单氨基酸替换降低CD229 CAR结合域亲和力,经固相结合试验和生物层干涉术筛选变异体,获得微摩尔亲和力的CD229 CAR结合域;该结合域联合c-Jun过表达后,在体外和体内对多发性骨髓瘤细胞的抗肿瘤活性与亲本CD229 CAR T细胞相当,但对健康淋巴细胞无亲本细胞的细胞毒活性。

要点

  • 单氨基酸替换降低CD229 CAR亲和力可提高对MM细胞的选择性。
  • 微摩尔亲和力CD229 CAR结合域联合c-Jun过表达保留抗MM活性。
  • 该变异CAR T细胞在体外和体内对健康淋巴细胞无细胞毒活性。

核心结论

  • 降低CD229 CAR结合域亲和力并联合c-Jun过表达,可获得与亲本CD229 CAR T细胞相当抗MM活性且对健康淋巴细胞无细胞毒活性的变异CAR T细胞,该策略需临床验证。

研究设计与样本

  • 采用单氨基酸替换方法改造CAR结合域,通过固相结合试验和生物层干涉术筛选变异结合域,并检测变异CAR T细胞对MM细胞和健康淋巴细胞的细胞毒活性(体外和体内)。

主要发现

  • 鉴定出具有微摩尔亲和力的CD229 CAR结合域,其联合c-Jun过表达后抗肿瘤活性与亲本CD229 CAR T细胞相当。
  • 该变异CD229 CAR T细胞在体外和体内对健康淋巴细胞缺乏亲本细胞的细胞毒活性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文指出该策略需要临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T cells expressing chimeric antigen receptors (CARs) have shown remarkable therapeutic activity against different types of cancer. However, the wider use of CAR T cells has been hindered by the potential for life-threatening toxicities due to on-target off-tumor killing of cells expressing low amounts of the target antigen. CD229, a signaling lymphocyte-activation molecule (SLAM) family member, has previously been identified as a target for CAR T cell-mediated treatment of multiple myeloma (MM) due to its high expression on the surfaces of MM cells. CD229 CAR T cells have shown effective clearance of MM cells in vitro and in vivo. However, healthy lymphocytes also express CD229, albeit at lower amounts than MM cells, causing their unintended targeting by CD229 CAR T cells. To increase the selectivity of CD229 CAR T cells for MM cells, we used a single amino acid substitution approach of the CAR binding domain to reduce CAR affinity. To identify CARs with increased selectivity, we screened variant binding domains using solid-phase binding assays and biolayer interferometry and determined the cytotoxic activity of variant CAR T cells against MM cells and healthy lymphocytes. We identified a CD229 CAR binding domain with micromolar affinity that, when combined with overexpression of c-Jun, confers antitumor activity comparable to parental CD229 CAR T cells but lacks the parental cells' cytotoxic activity toward healthy lymphocytes in vitro and in vivo. The results represent a promising strategy to improve the efficacy and safety of CAR T cell therapy that requires clinical validation.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Vander Mause ER, Baker JM, Dietze KA, et al. Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity. Sci Transl Med. 2023. PMID: 37467316. doi:10.1126/scitranslmed.add7900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。